NEW YORK, May 2 – Paradigm Genetics’ gene function discovery partnerships with Monsanto and Bayer began to pay off as its first quarter revenues surged to $5.5 million, compared to $593,000 for the first quarter of 2000, the company said Wednesday.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times reports that as China invests in science, it also is dealing with research fraud.
In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.
The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.
Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.